High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma.
The incidence of malignant mesothelioma has increased greatly in the last 40 years. Current and recent past exposure to asbestos is expected to substantially increase this incidence. We report nine cases of malignant mesothelioma which temporarily responded to treatment with high-dose methotrexate-citrovorum rescue and vincristine. Further clinical trials of high-dose methotrexate with citrovorum rescue appear indicated in this disease.
D000328:Adult; D000368:Aged; D001194:Asbestos / Q000009:adverse effects; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy; D010997:Pleural Neoplasms / Q000188:drug therapy; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D001194:Asbestos; D014750:Vincristine; D002955:Leucovorin; D008727:Methotrexate